Biotech Set to Capture 50% of Top 100 Drugs by 2014
The percentage of sales from biotechnology products (bioengineered vaccines + biologics), within the world’s top 100 drugs, is set to increase from 28% in 2008 to 50% by 2014, according to a new report from EvaluatePharma. In the broader market, sales from biotechnology products are expected to capture 23% of the world pharmaceutical market by 2014, versus its current share of 17% in 2008, EvaluatePharma says in its World Preview 2014 (free with registration). The total value of biotechnology sales is set to grow 56% between 2008 and 2014 from $108bn to $169bn.
Highlights of the report:
- Worldwide Prescription Drug Sales total $707bn in 2014; 2.9% (CAGR) over 2009 – 2014
- Global Prescription Drug Sales Flat in 2009
- Over $182bn of Sales at Risk from Patent Expirations in 2011-14
- Pfizer (NYSE: PFE) Maintains Top Spot in 2014 via Wyeth Acquisition
- Novartis (NYSE: NVS) Moves up to Second Place as Merck+Schering Plough (NYSE: MRK) Drops to Third
- Biotech Products Set to Overtake Small Molecule within Top 100 Drugs by 2014
- Global Pharmaceutical R&D Spend to Grow by 2.4% (CAGR) to $142bn by 2014
- Vaccines Set to Record Highest Growth of Major Therapy Categories to 2014
- Sales Potential of 2008 New Drugs (NMEs) Down 14% vs. 2007 Cohort of NMEs
See Alacra StreetPulse for Latest Analyst Comments on Pfizer, Novartis and Merck.
You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
